Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Jul 16, 2026 7:05 AM EDT

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Conference Call and Webcast Information:

Date: Thursday, August 6, 2026 at 4:30 PM ET

Participant Dial-in (US): 1-800-717-1738

Participant Dial-in (International): 1-646-307-1865

Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar .

About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact: Brian Ritchie LifeSci Advisors [email protected]

Media Inquiries: Corporate Communications media@relmada.com

Source: Relmada Therapeutics

Released July 16, 2026